Biotech Acquisitions
When a company buys a listed biotech, it either offers to buy the shares directly (a tender offer) or the shareholders vote on a merger. Both are filed with the SEC, with the price and the buyer's name.
Who bought whom since 2016: 451 tender offers and mergers for listed drug, device and life-science tools companies, read from their SEC filings, plus private companies bought in deals announced on the wires since Arca began mirroring them.
- Listed companies bought, last 12 months: 51
- Their combined value: $177B
- Still pending: 15
- Largest, last 12 months: $20B
Listed companies bought per year
By the year the deal was announced.
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
- Full year
- 2026 to date, through Nov 19, 2026
Deal value per year
Billions of dollars, upfront; contingent value rights are not counted. A few megadeals make most years.
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
By disease area, last 3 years
The area most of the bought company's registered trials are in.
- $35B1935%
- $11B815%
- $18B59%
- $12B47%
- $26B36%
- $3.2B36%
- $9.3B36%
- $4.5B36%
- $6.8B24%
- $1.4B24%
Most frequent buyers since 2016
Listed companies bought, and what was paid.
- Eli Lilly$31B15
- Sanofi$41B11
- Merck$41B9
- Pfizer$101B9
- Bristol-Myers Squibb Company$73B7
- AbbVie$56B6
- Gilead Sciences$49B6
- Novartis$34B6
- Boston Scientific$20B5
- Concentra Biosciences, LLC$845M5
Largest, last 12 months
By deal value.
- Exact SciencesAbbott Laboratories$20B
- HologicHopper Parent Inc.$17B
- PenumbraBoston Scientific Corporation$15B
- BIO-TECHNEMerck KGaA, Darmstadt, Germany$11B
- Avidity BiosciencesNovartis AG$11B
- NuvalentGsk$11B
- MasimoDanaher Corporation$9.4B
- Crinetics PharmaceuticalsVertex Pharmaceuticals$9.0B
Every acquisition
Newest first. Value is the transaction value in the filing-fee table, the value the filing or release states, or the price times the shares outstanding; hover a value for which.459 acquisitions
| Per share | Sources | ||||||
|---|---|---|---|---|---|---|---|
| Nov 17, 2026 | Form BioPrivate company | Astromech | Not stated | โ | โ | Pending | PR Newswire |
| Nov 17, 2026 | Gallant Pet, Inc.Private company | Dechra | Not stated | โ | โ | Pending | PR Newswire |
| Nov 16, 2026 | Calytrix BioPrivate company | Lilly | Not stated | โ | Hematology | Pending | PR Newswire |
| Nov 16, 2026 | Contego MedicalPrivate company | Medtronic | Not stated | โ | Cardiovascular | Pending | PR Newswire |
| Nov 16, 2026 | Ollin BiosciencesPrivate company | Johnson & Johnson | $2.2B | โ | Ophthalmology | Pending | Business Wire |
| Nov 12, 2026 | Nexus PharmaceuticalsPrivate company | PAI Pharma | Not stated | โ | โ | Pending | PR Newswire |
| Nov 12, 2026 | NeuroAirmid Therapeutics, Inc.Private company | Lineage Cell Therapeutics, Inc. | Not stated | โ | Neurology | Pending | Business Wire |
| Nov 10, 2026 | OmniosePrivate company | AstraZeneca | Not stated | โ | Infectious disease | Pending | Business Wire |
| Oct 30, 2026 | Lifecore Biomedical, Inc. | Lifecore Inc. | $238M | $6.28 | โ | Pending | DEFM14A |
| Oct 21, 2026 | Personalis, Inc.Tools and diagnostics | Tempus AI, Inc. | $1.7B | $16.25 | โ | Pending | DEFM14A |
| Oct 8, 2026 | Pacira BioSciences, Inc. | Viatris Inc. | $1.6B | $36.50 | โ | Closed Nov 17 | Schedule TO ยท PR Newswire |
| Sep 11, 2026 | Supernus Pharmaceuticals, Inc. | Indivior Pharmaceuticals, Inc. | Not stated | โ | Psychiatry | Closed Nov 2 | DEFM14A |
| Sep 4, 2026 | Biolife Solutions IncMedtech | Repligen Corporation | $550M | $11.25 | โ | Closed Oct 6 | DEFM14A |
| Sep 4, 2026 | Sanara MedTech Inc.Medtech | MiMedx Group, Inc. | $303M | $33 | โ | Pending | DEFM14A |
| Sep 3, 2026 | Integer Holdings CorpMedtech | Armstrong Parent, Inc. | $4.3B | $127 | โ | Closed Nov 17 | DEFM14A |
| Aug 26, 2026 | Lantheus Holdings, Inc. | Curium | $6.7B | $102.50 + $12 CVR | โ | Pending | DEFM14A |
| Aug 14, 2026 | LogicMark, Inc.Medtech | Langham Project, LLC | $1M | $1.31 | โ | Pending | DEFM14A |
| Aug 11, 2026 | Theravance Biopharma, Inc. | Zymeworks Inc. | $883M | $17 | โ | Closed Sep 23 | DEFM14A |
| Aug 10, 2026 | BIO-TECHNE Corp | Merck KGaA, Darmstadt, Germany | $11.4B | $73 | โ | Pending | DEFM14A |
| Jul 30, 2026 | AtaiBeckley Inc. | Eli Lilly and Company | $2.5B | $6.75 + $2.50 CVR | โ | Closed Sep 11 | DEFM14A |
| Jul 27, 2026 | Forte Biosciences, Inc. | argenx | $2.2B | $77 | Dermatology | Closed Aug 27 | Schedule TO |
| Jul 21, 2026 | Crinetics Pharmaceuticals, Inc. | Vertex Pharmaceuticals | $9.0B | $85 | Metabolic and endocrine | Closed Sep 1 | DEFM14A |
| Jul 21, 2026 | Senti Biosciences Holdings, Inc. | โ | Not stated | โ | โ | Pending | DEFM14A |
| Jul 2, 2026 | Apogee Therapeutics, Inc. | AbbVie Inc. | Not stated | $135.11 | Immunology | Closed Sep 3 | DEFM14A |
| Jun 18, 2026 | Amneal Pharmaceuticals, Inc. | โ | Not stated | โ | โ | Pending | DEFM14A |
| Jun 9, 2026 | Nuvalent, Inc. | Gsk | $10.6B | $124 | Oncology | Closed Jul 15 | Schedule TO |
| Jun 1, 2026 | Organon & Co. | Sun Pharma | $3.7B | $14 | Immunology | Pending | DEFM14A |
| May 29, 2026 | Esperion Therapeutics, Inc. | Essence Parent Inc. | $813M | $3.16 | Metabolic and endocrine | Closed Jul 13 | DEFM14A |
| May 29, 2026 | Avanos Medical, Inc.Medtech | A-AV Holdco I, Inc. | $1.2B | $25 | โ | Closed Jul 27 | DEFM14A |
| May 28, 2026 | Catalyst Pharmaceuticals, Inc. | Angelini Pharma S.p.A. | $3.9B | $31.50 | Neurology | Closed Jul 15 | DEFM14A |
| May 15, 2026 | Cumberland Pharmaceuticals Inc | Apotex | $100M | โ | โ | Pending | DEFM14A |
| Apr 29, 2026 | KalVista Pharmaceuticals, Inc. | Chiesi Farmaceutici S.p.A. | $1.9B | $27 | โ | Closed Jun 11 | Schedule TO |
| Apr 17, 2026 | Centessa Pharmaceuticals plc | Eli Lilly and Company | $5.9B | $38 + $9 CVR | โ | Closed Jun 24 | DEFM14A |
| Apr 9, 2026 | Assertio Holdings, Inc. | Zydus Lifesciences Ltd. | $163M | $23.50 | โ | Closed Jul 7 | Schedule TO |
| Apr 6, 2026 | Soleno Therapeutics Inc | Neurocrine Biosciences, Inc. | $2.9B | $53 | Neurology | Closed May 18 | Schedule TO |
| Apr 1, 2026 | Penumbra IncMedtech | Boston Scientific Corporation | $14.7B | $374 | โ | Pending | DEFM14A |
| Mar 31, 2026 | Apellis Pharmaceuticals, Inc. | Biogen Inc. | $5.8B | $41 + $4 CVR | Renal and urology | Closed May 14 | Schedule TO |
| Mar 30, 2026 | Kezar Life Sciences, Inc. | Aurinia Pharma U.S., Inc. | $55M | $6.96 | Immunology | Closed May 11 | Schedule TO |
| Mar 25, 2026 | Terns Pharmaceuticals, Inc. | Merck | $6.7B | $53 | โ | Closed May 5 | Schedule TO |
| Mar 18, 2026 | Masimo CorpMedtech | Danaher Corporation | $9.4B | $180 | โ | Closed Jun 10 | DEFM14A |
| Feb 26, 2026 | Fonar CorpMedtech | โ | Not stated | $19 | โ | Closed Jun 3 | DEFM14A |
| Feb 23, 2026 | Arcellx, Inc. | Gilead Sciences, Inc. | $7.8B | $115 + $5 CVR | โ | Closed Apr 28 | Schedule TO |
| Jan 30, 2026 | BioAtla, Inc. | โ | Not stated | โ | Oncology | Pending | DEFM14A |
| Jan 28, 2026 | Lifeward Ltd.Medtech | Oramed Pharmaceuticals Inc. | Not stated | โ | โ | Pending | DEFM14A |
| Jan 22, 2026 | Ventyx Biosciences, Inc. | Eli Lilly and Company | $999M | $14 | Dermatology | Closed Mar 4 | DEFM14A |
| Jan 21, 2026 | Amicus Therapeutics, Inc. | BioMarin Pharmaceutical Inc. | $4.5B | $14.50 | โ | Closed Apr 27 | DEFM14A |
| Jan 21, 2026 | Lisata Therapeutics, Inc. | Kuva Labs Inc. | $32M | $4 + $3 CVR | Oncology | Pending | Schedule TO |
| Jan 20, 2026 | RAPT Therapeutics, Inc. | Gsk | $2.2B | $58 | โ | Closed Mar 3 | Schedule TO |
| Dec 29, 2025 | Exact Sciences CorpTools and diagnostics | Abbott Laboratories | $19.9B | $105 | โ | Closed Mar 23 | DEFM14A |
| Dec 29, 2025 | Dynavax Technologies Corp | Sanofi | $2.3B | $15.50 | โ | Closed Feb 10 | Schedule TO |
A listed company is bought by a tender offer (Schedule TO-T, filed by the buyer) or a merger its holders vote on (a DEFM14A proxy); both name the company and the buyer. Included: companies whose SEC industry code is drugs and biologics (2833 to 2836), devices (3841 to 3845, 3851) or research tools and labs (3826, 8731, 8071). A reverse merger, where a private company takes over a listed one, is left out. The value is the transaction value from the filing-fee table when there is one, else the value the filing states, else the price per share times the shares outstanding. A model reads the buyer, the price and any contingent value right from the opening of the offer or proxy, and a fact is kept only when it quotes the filing word for word. Closed means the company later delisted (Form 25) or deregistered (Form 15). Private companies come from releases since Nov 10, 2026. Disease area is the MeSH branch of most of the company's trials on ClinicalTrials.gov. Venture rounds and IPOs are on Biotech funding. Refreshed weekly. SEC EDGAR (Schedule TO-T, DEFM14A, Forms 25 and 15), PR Newswire, Business Wire and ClinicalTrials.gov ยท Updated Nov 19, 2026